Ro-3306

Name: Ro-3306
Brand: Selleck Chemicals
SKU: S7747
Rating: 5 (31 reviews)

For research use only. Not for use in humans.

Catalog No.S7747

31 publications

Molecular Weight(MW): 351.45

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases.

Selleck's Ro-3306 has been cited by 31 publications

Nature, 2016, 539(7627):54-58

PubMed: 27760120 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Mol Cell, 2019, 10.1016/j.molcel.2019.10.016

PubMed: 31733992 ( click the link to review the publication )

Mol Cell, 2019, 75(2):267-283

PubMed: 31202576 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2253

PubMed: 31138795 ( click the link to review the publication )

Nucleic Acids Res, 2019, 10.1093/nar/gkz602

PubMed: 31291454 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2019, 10.1073/pnas.1915108116

PubMed: 31712441 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2019, 116(27):13374-13383

PubMed: 31209037 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472.CAN-18-2486

PubMed: 31253668 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472

PubMed: 31484670 ( click the link to review the publication )

Cancers (Basel), 2019, 11(11)

PubMed: 31703356 ( click the link to review the publication )

J Virol, 2019, 93(14)

PubMed: 31043526 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4511

PubMed: 30375385 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(20):10724-10739

PubMed: 30202980 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(9)

PubMed: 30108112 ( click the link to review the publication )

FEBS Lett, 2018, 592(11):1893-1904

PubMed: 29782647 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(12)

PubMed: 30545129 ( click the link to review the publication )

Cancer research, 2018, 10.1158/0008-5472.CAN-17-2288

PubMed: ( click the link to review the publication )

FASEB J, 2018, 10.1096/fj.201801369R

PubMed: 30496702 ( click the link to review the publication )

Nat Commun, 2017, 8(1):2039

PubMed: 29229926 ( click the link to review the publication )

EBioMedicine, 2017, 19:18-30

PubMed: 28434945 ( click the link to review the publication )

Mol Cell Biol, 2017, 37(20)

PubMed: 28760773 ( click the link to review the publication )

Cell Signal, 2017, 39:74-83

PubMed: 28780319 ( click the link to review the publication )

Oncotarget, 2017, 8(63):107206-107222

PubMed: 29291023 ( click the link to review the publication )
Oncotarget, 2017, 8(53):90662-90673

PubMed: 29207595 ( click the link to review the publication )

Sci Rep, 2017, 7:41950

PubMed: 28176818 ( click the link to review the publication )

Nat Commun, 2016, 7:12880

PubMed: 27634057 ( click the link to review the publication )

Arthritis Rheumatol , 2016, 68(5):1222-32

PubMed: 26663909 ( click the link to review the publication )

Cell Cycle, 2016, 15(20):2742-52

PubMed: 27580187 ( click the link to review the publication )

PLoS One, 2016, 11(2):e0149099

PubMed: 26881434 ( click the link to review the publication )

J Cell Biol, 2015, 209(2):221-34

PubMed: 25918224 ( click the link to review the publication )

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Description

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases.

Targets

CDK1 ^[1] (Cell-free assay)	PKCδ ^[1] (Cell-free assay)	SGK ^[1] (Cell-free assay)	ERK ^[1] (Cell-free assay)
20 nM(Ki)	318 nM(Ki)	497 nM(Ki)	1980 nM(Ki)

In vitro

RO-3306 inhibits CDK1/cyclin B1, CDK1/cyclin A, CDK2/cyclin E, and CDK4/cyclin D activity with Ki of 35 nM, 110 nM, 340 nM, and over 2000 nM, respectively. Treatment of HCT116, SW480, and HeLa cells with RO-3306 for 20 h leads to a complete block of the cell cycle in the G2/M phase. The proliferation of both HCT116 and SW480 is effectively blocked by RO-3306. RO-3306 appears to be more proapoptotic in cancer cells (HCT116 and SW480) than nontumorigenic cells (MCF 10A and MCF 12A).^[1] RO-3306 effectively arrests oocyte maturation at a concentration of 10 μM.^[2]

Cell Data

Cell Lines	Assay Type	Incubation Time	Activity Description	PMID
human NCI-SNU-1 cell	MoHSS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MnTXTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvU17VMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjd\|MEm1JO69VQ>?	NFWzdWpUSU6JRWK=
human H460a cells	MoXOVJJwdGmoZYLheIlwdiCjc4PhfS=>		NXHJT3pYSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIOFYx[SClZXzsd{whUUN3ME2xMlA1KM7:TR?=	NH:zVWkyPzNyM{SyNS=>
human MDA435 cells	MoD3VJJwdGmoZYLheIlwdiCjc4PhfS=>		MnSxRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPRFG0N\|Uh[2WubIOsJGlEPTB;MT6xOEDPxE1?	MlHoNVc{ODN2MkG=
human HCT116 cells	M1rFe3Bzd2yrZnXyZZRqd25iYYPzZZk>		M1fSUGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzMEBKSzVyPUGuNVQh\|ryP	NFvGV5EyPzNyM{SyNS=>
human H4 cell	M1jxO2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MWfJcohq[mm2aX;uJI9nKGi3bXHuJGg1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5zNUi3OUDPxE1?	NFfLb3VUSU6JRWK=
human PA-1 cell	NGfBTZFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NHPiN3NKdmirYnn0bY9vKG:oIHj1cYFvKFCDLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlIzPjV2IN88US=>	MXvTRW5ITVJ?
human T98G cell	M1LWT2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NXTjRXNYUW6qaXLpeIlwdiCxZjDoeY1idiCWOUjHJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4{PjhzMjFOwG0>	MUnTRW5ITVJ?
human SW1710 cell	NXjRPGZOT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NVzielJCUW6qaXLpeIlwdiCxZjDoeY1idiCVV{G3NVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjZzNEC4JO69VQ>?	Mn7QV2FPT0WU
human U251 cell	MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		Mli0TY5pcWKrdHnvckBw\iCqdX3hckBWOjVzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT62N\|c4OSEQvF2=	M{HvVHNCVkeHUh?=
human ALL-PO cell	NELjTVRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M3;PbmlvcGmkaYTpc44hd2ZiaIXtZY4hSUyOLWDPJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZnwxIxiSVO1NF0yNjlyOEGzJO69VQ>?	M4jPXXNCVkeHUh?=
human RKO cells	MkD3VJJwdGmoZYLheIlwdiCjc4PhfS=>		NHnrUnhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGLLU{Bk\WyuczygTWM2OD1{IN88US=>	MUOxO\|MxOzR{MR?=
human SK-N-DZ cell	M3jvUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NGDZOnBKdmirYnn0bY9vKG:oIHj1cYFvKFONLV6tSHoh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjBzOEe2JO69VQ>?	MWHTRW5ITVJ?
human A4-Fuk cell	M1fiRWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NGD1ZWdKdmirYnn0bY9vKG:oIHj1cYFvKEF2LV\1b{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvODV4MESg{txO	Ml\4V2FPT0WU
human SW480 cells	NFTqNINRem:uaX\ldoF1cW:wIHHzd4F6		Ml:2RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCVV{S4NEBk\WyuczygTWM2OD1{LkKg{txO	NHTY[lUyPzNyM{SyNS=>
human 639-V cell	NGXqOpVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MlvMTY5pcWKrdHnvckBw\iCqdX3hckA3OzlvVjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuNlc2OzdizszN	MXfTRW5ITVJ?
human Hs-578-T cell	MlXoS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NXrzUnQyUW6qaXLpeIlwdiCxZjDoeY1idiCKcz21O\|guXCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTJwMke3PVkh\|ryP	MmDEV2FPT0WU
human UM-UC-3 cell	NEH1WmZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MoPWTY5pcWKrdHnvckBw\iCqdX3hckBWVS2XQz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZnwxIxiSVO1NF0zNjd\|OUO2JO69VQ>?	NVvq[nRNW0GQR1XS
human BPH-1 cell	Mo\nS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		Ml:yTY5pcWKrdHnvckBw\iCqdX3hckBDWEhvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuPVc1PTVizszN	NU[2eopZW0GQR1XS
human 5637 cell	M37xOmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M1;rZ2lvcGmkaYTpc44hd2ZiaIXtZY4hPTZ\|NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUOuNFg2OzJizszN	M1HjSXNCVkeHUh?=
human 8-MG-BA cell	NELJbHlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MYDJcohq[mm2aX;uJI9nKGi3bXHuJFguVUdvQlGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4Phfg+9lCCLQ{WwQVMvOTRyNEmg{txO	MYjTRW5ITVJ?
human HCT116 cells	M4PE[mN6fG:2b4jpZ:Kh[XO\|YYm=	NHfzNpk2KGSjeYO=	M1XDSGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhEXDFzNjDj[YxteyCjZoTldkA2KGSjeYOgZpkhVVSVIHHzd4F697zOIFnDOVA:Oy5{IN88US=>	NX7OSpRrOjJ\|Mk[xOlg>
human LB1047-RCC cell	Mn2wS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NYLFT\|JKUW6qaXLpeIlwdiCxZjDoeY1idiCOQkGwOFcuWkOFIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mz6yN\|UxOSEQvF2=	MVXTRW5ITVJ?
human KOSC-2 cell	MX\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NV;NbpVWUW6qaXLpeIlwdiCxZjDoeY1idiCNT2PDMVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjR2Nk[2NkDPxE1?	MUPTRW5ITVJ?
human COR-L88 cell	M3PlTWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NXjm[XhRUW6qaXLpeIlwdiCxZjDoeY1idiCFT2KtUFg5KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy52N{W4N{DPxE1?	NE\jTZRUSU6JRWK=
human PSN1 cell	NVrYfZliT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		Mn7kTY5pcWKrdHnvckBw\iCqdX3hckBRW05zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;ND6xNFgxPSEQvF2=	NVfnbGMxW0GQR1XS
human LXF-289 cell	MoGwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NG\ReHFKdmirYnn0bY9vKG:oIHj1cYFvKEy[Rj2yPFkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjJzN{[g{txO	NV3MXZRbW0GQR1XS
human MN-60 cell	Ml;PS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MYTJcohq[mm2aX;uJI9nKGi3bXHuJG1PNTZyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;ND6zO\|YzOyEQvF2=	MWrTRW5ITVJ?
human NEC8 cell	NIDkWXZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M4jrOmlvcGmkaYTpc44hd2ZiaIXtZY4hVkWFODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUSuOFcxPzZizszN	MVnTRW5ITVJ?
human SJSA1 cells	NHzCN\|ZRem:uaX\ldoF1cW:wIHHzd4F6		NXT6cWNISW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTTnNCOSClZXzsd{whUUN3ME20MlU2KM7:TR?=	MlzENVc{ODN2MkG=
human NCI-H2405 cell	Moj2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NHPtZ3VKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlQxPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTRwN{S0PVMh\|ryP	M4fSTHNCVkeHUh?=
human YH-13 cell	MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M4m4XGlvcGmkaYTpc44hd2ZiaIXtZY4hYUhvMUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlc2Pzd4IN88US=>	MnOwV2FPT0WU
human SK-MEL-2 cell	NVfrfpRIT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NFTN[XhKdmirYnn0bY9vKG:oIHj1cYFvKFONLV3FUE0zKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS5yOU[zNkDPpG1?	MV;TRW5ITVJ?
human NB13 cell	M2Pj[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M{LOOGlvcGmkaYTpc44hd2ZiaIXtZY4hVkJzMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUWuN\|I4QDZizszN	MUjTRW5ITVJ?
human GAMG cell	MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MlPBTY5pcWKrdHnvckBw\iCqdX3hckBISU2JIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;NT6zO\|E2KM7:TR?=	NFj4eXpUSU6JRWK=
human NCI-H1792 cell	NXnE[\|Q{T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NVq3XpFRUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE4QTJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13LkS3PVU1KM7:TR?=	MX3TRW5ITVJ?
human KP-4 cell	NUD3XVVkT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NX3nUXpNUW6qaXLpeIlwdiCxZjDoeY1idiCNUD20JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU43QTh{MzFOwG0>	NFy3W3VUSU6JRWK=
human HGC-27 cell	NInHbWRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Mmj5TY5pcWKrdHnvckBw\iCqdX3hckBJT0NvMkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Mlc{ODd5IN88US=>	M2rmTHNCVkeHUh?=
human GCT cell	MnL3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MlPxTY5pcWKrdHnvckBw\iCqdX3hckBIS1RiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13Lki1NVIyKM7:TR?=	MlXTV2FPT0WU
human PFSK-1 cell	M3zTPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MX\Jcohq[mm2aX;uJI9nKGi3bXHuJHBHW0tvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUWuPFYyPjhizszN	NGezPXlUSU6JRWK=
human A172 cell	M1PWTGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NG\vVmdKdmirYnn0bY9vKG:oIHj1cYFvKEFzN{KgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlkxPzlizszN	NVHVXXBuW0GQR1XS
human HO-1-N-1 cell	MUTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NIr5NGRKdmirYnn0bY9vKG:oIHj1cYFvKEiRLUGtUk0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS57NUSyOUDPxE1?	M2TIXnNCVkeHUh?=
human HN cell	MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MV\Jcohq[mm2aX;uJI9nKGi3bXHuJGhPKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS57N{C5O{DPxE1?	NHXrXYhUSU6JRWK=
human IST-MES1 cell	NYXuWJlMT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NEDiZoNKdmirYnn0bY9vKG:oIHj1cYFvKEmVVD3NSXMyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS57N{WyNUDPxE1?	MV3TRW5ITVJ?
human TGW cell	M3XkcWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NGroV3pKdmirYnn0bY9vKG:oIHj1cYFvKFSJVzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPU[uNFU3QDJizszN	NGDubmNUSU6JRWK=
human COR-L23 cell	MlmxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M1O3[WlvcGmkaYTpc44hd2ZiaIXtZY4hS0:ULVyyN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvOzd\|NTFOwG0>	NIX3UJhUSU6JRWK=
human D-566MG cell	MkX0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MXTJcohq[mm2aX;uJI9nKGi3bXHuJGQuPTZ4TVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22Mlc5QDd\|IN88US=>	MYXTRW5ITVJ?
human SKG-IIIa cell	MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NXvjWGk6UW6qaXLpeIlwdiCxZjDoeY1idiCVS1etTWlK[SClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTZwOEW1O\|Ih\|ryP	Mn21V2FPT0WU
human NCI-H446 cell	NEn3dVRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NXrWVZBSUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFQ1PiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTdwMEG4NUDPxE1?	M{\zdXNCVkeHUh?=
human KYSE-270 cell	MXrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NYPrZo5WUW6qaXLpeIlwdiCxZjDoeY1idiCNWWPFMVI4OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTdwMEO4O\|Ih\|ryP	MY\TRW5ITVJ?
human CAL-39 cell	MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M2nXeGlvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUO5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{4{PTJ2IN88US=>	MmTSV2FPT0WU
human IST-SL1 cell	NXPkeVJQT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MWjJcohq[mm2aX;uJI9nKGi3bXHuJGlUXC2VTEGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlQ{OzR7IN88US=>	M17FZXNCVkeHUh?=
human SF539 cell	M3;VV2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MVrJcohq[mm2aX;uJI9nKGi3bXHuJHNHPTN7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Nz61OVE6PyEQvF2=	NI\CR2VUSU6JRWK=
human TE-1 cell	M{HuOWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M1zr[mlvcGmkaYTpc44hd2ZiaIXtZY4hXEVvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUeuPFkxQTFizszN	MXXTRW5ITVJ?
human NB10 cell	NYHzXYdqT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M3\1[mlvcGmkaYTpc44hd2ZiaIXtZY4hVkJzMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUeuPVg4PThizszN	NEXkRYpUSU6JRWK=
human 8505C cell	NHSydXdIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M2jDWWlvcGmkaYTpc44hd2ZiaIXtZY4hQDVyNVOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23Mlk6QDF5IN88US=>	NVj1b2s2W0GQR1XS
human DB cell	NH;hbVRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MWXJcohq[mm2aX;uJI9nKGi3bXHuJGRDKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:QC5yMUGzNUDPxE1?	NHnEcW5USU6JRWK=
human NCI-H28 cell	NYjmUmh6T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MmiyTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEK4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PE42QTh6NDFOwG0>	NGfVfW9USU6JRWK=
human LOXIMVI cell	M4nMc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MljkTY5pcWKrdHnvckBw\iCqdX3hckBNV1iLTW\JJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PE43OzdyMTFOwG0>	MVXTRW5ITVJ?
human ME-180 cell	M3jNOWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NYK2V\|lrUW6qaXLpeIlwdiCxZjDoeY1idiCPRT2xPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF05NjhyM{m1JO69VQ>?	NGPseHNUSU6JRWK=
human ES3 cell	NGTifIJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NGDYbYpKdmirYnn0bY9vKG:oIHj1cYFvKEWVMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUmuNVI4QTRizszN	NX[yTFJqW0GQR1XS
human SK-N-FI cell	Ml[0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NYnJepFYUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3OMWZKKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:QS52MU[5PUDPxE1?	MnTyV2FPT0WU
human NBsusSR cell	NYTmXmZ1T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NILz[HBKdmirYnn0bY9vKG:oIHj1cYFvKE6Ec4XzV3Ih[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yOC5{M{G4JO69VQ>?	M{LFXXNCVkeHUh?=
human MCF7 cell	MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NHLOVYZKdmirYnn0bY9vKG:oIHj1cYFvKE2FRkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNU4yQDR7IN88US=>	Mn:1V2FPT0WU
human A549 cell	NULSO5R1T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NWX3boVmUW6qaXLpeIlwdiCxZjDoeY1idiCDNUS5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVEvOjB4IN88US=>	NYLVTGhXW0GQR1XS
human HuP-T4 cell	MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MU\Jcohq[mm2aX;uJI9nKGi3bXHuJGh2WC2WNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGwMlQzPzFizszN	NFXQPFBUSU6JRWK=
human HSC-2 cell	MVnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NU\IZnl7UW6qaXLpeIlwdiCxZjDoeY1idiCKU1OtNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEyNDd6NEKg{txO	NEHZTWRUSU6JRWK=
human A253 cell	Mli1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NWfrNJNQUW6qaXLpeIlwdiCxZjDoeY1idiCDMkWzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVUvOjh\|NDFOwG0>	NXfWTplRW0GQR1XS
human HCT-116 cell	NWCxZ5hLT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M1y3emlvcGmkaYTpc44hd2ZiaIXtZY4hWENvMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUG4MlAxPDNizszN	MkKyV2FPT0WU
human HCT-116 cell	NGPKXYxIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M2TBXmlvcGmkaYTpc44hd2ZiaIXtZY4hUEOWLUGxOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE6NjZ4ODFOwG0>	MVnTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-Cdk1 / Cdk1 / Cleaved PARP / Cleaved caspase-3 / p-p38 / Bad / Apaf1-1 / p-H2Ax / Bim / Bad; PubMed: 27385216 Oncotarget OVCA-429 and OVCAR-3 were exposed to RO-3306 for 24 h in indicated dose dependent manner, (F) 10 uM RO-3306 for 12 h up to 48 h. The expression level of the indicated protein and the phosphorylated form of H2A.x and p38 were examined via Western blot analyses.	27385216
Immunofluorescence	PARP1 / Plk1 ; PubMed: 28069876 Mol Cancer Ther Representative images of IF staining for PARP1 and Plk1 in 22RV1 cells treated with 0.3 mM mimosine for 20 h, 4 mM hydroxyurea for 24 h, 10 µM RO-3306 for 7 h or 200 ng/ml nocodazole (Noc) for 12 h.	28069876
Growth inhibition assay	Cell viability; PubMed: 27385216 Oncotarget OVCA-429 and OVCAR-3 were exposed to RO-3306 in indicated time- and dose-dependent manner. Cell viability were measured via crystal violet assay. Results are the means ± S.E. n = 3.	27385216

Protocol

Kinase Assay:^[1]

- Collapse

CDK assay:

The activity of CDK1 cyclin B1, CDK1 cyclin A, CDK2 cyclin E, and CDK4 cyclin D is measured by a homogeneous time-resolved fluorescence assay in a 96-well format. The assay buffer contained 25 mM Hepes, 6.25 mM MgCl2, 0.003% Tween 20, 0.3 mg/mL BSA, 1.5 mM DTT, and ATP as follows: 162 μM (CDK1), 90 mM (CDK2), or 135 μM (CDK4). CDK1 and CDK2 buffer contained 10 mM MgCl2. Test compounds are diluted in assay buffer to 3-fold their final concentration in 20 μL, and the reaction is started by the addition of a 40 μL assay buffer containing the pRB substrate (0.185μM). The plates are incubated at 37°C for 30 min with constant agitation, and the reaction is terminated by the addition of 15 μL of 1.6μM anti-phospho pRB antibody (Ser-780) in 25 mM Hepes, 24 mM EDTA, and 0.2 mg/mL BSA. After an additional 30 min of incubation with shaking, 15μL of 3nM Lance-Eu-W1024-labeledanti-rabbitIgG and 60 nM Alophycocyanin-conjugated anti-His-6 antibody in 25 mM Hepes, and 0.5 mg/mL BSA is added and incubated for 1 h. The plates are read in the Victor-V multi- label reader at excitation 340 nm and emission 615 nm and 665 nm. The IC50 values are calculated from the readings at 665 nm and normalized for Europium readings at 615 nm. Ki values are calculated according to the equation: Ki= IC50/(1 + S/Km ), where S is the ATP concentration in the assay and Km is the Michaelis-Menten constant for ATP. The inhibitory activity against the panel of kinases is determined by the IMAP assay technology.

Cell Research:^[3]

- Collapse

Cell lines: MDA-MB-231 cell line
Concentrations: 20 μM
Incubation Time: 72 h
Method: Log phases cells (25,000) are seeed in 96-well plates and incubated in a 37℃ incubator with CO2, After 24 h, different concentrations of RO-3306 are administered to determine the drug concentrations required to achieve a 50% growth inhibition (IC50). MTT (20 μL, 5mg/mL stock solution in saline) is added to each well and the cells are incubated for 4 h. Supernatants are removed and formazan crystals from viable cells are solubilized with 200 μL anhydrous DMSO. The absorbance is detected with a 550 model microplate reader at the 565 nm wavelength.
(Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	13 mg/mL warmed (36.98 mM)
	Water	Insoluble
	Ethanol	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Ro-3306 SDF

Molecular Weight	351.45
Formula	C₁₈H₁₃N₃OS₂
CAS No.	872573-93-8
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A
Smiles	O=C1N=C(NCC2=CC=CS2)S\C1=C/C3=CC=C4N=CC=CC4=C3

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

CDK Signaling Pathway Map

Related CDK Products

SU9516 ^New

SU 9516 is a 3-substituted indolinone CDK inhibitor with IC50 of 22 nM, 40 nM, and 200 nM for CDK2, CDK1, and CDK4, respectively.
Purvalanol A ^New

Purvalanol A is a potent, and cell-permeable CDK inhibitor with IC50 of 4 nM, 70 nM, 35 nM, and 850 nM for cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, and cdk4-cyclin D1, respectively.
AT7519 HCl ^New

AT7519 HCl is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9 with IC50 of 10-210 nM in cell-free assays. It is less potent to CDK3 and little active to CDK7. Phase 2.
Palbociclib (PD-0332991) HCl

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Features:Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).
Palbociclib (PD0332991) Isethionate

Palbociclib (PD0332991) Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Features:The 1st specific inhibitor for CDK4/6 to show promise in multiple cancers.
Dinaciclib (SCH727965)

Dinaciclib (SCH727965) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM in cell-free assays, respectively. It also blocks thymidine (dThd) DNA incorporation. Phase 3.
Flavopiridol HCl

Flavopiridol HCl competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM in cell-free assays. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Phase 1/2.
Roscovitine (Seliciclib,CYC202)

Roscovitine (Seliciclib, CYC202) is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM in cell-free assays. It shows little effect on CDK4/6. Phase 2.
abemaciclib mesylate (LY2835219)

abemaciclib (LY2835219) is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively. Phase 3.
Ribociclib (LEE011)

Ribociclib (LEE011) is an orally available, and highly specific CDK4/6 inhibitor. Phase 3.

Choose Your Country or Region

By Signaling Pathways

By product type

Ro-3306